PTIX

Protagenic Therapeutics, Inc. (PTIX) is an emerging biopharmaceutical company based in New York that focuses on developing groundbreaking therapies for stress-related mood and neuropsychiatric disorders. By leveraging advanced research methodologies and state-of-the-art technologies, Protagenic aims to fulfill critical unmet medical needs in mental health, a sector that has garnered increasing attention due to its societal impact. With a dedicated approach to enhancing patient outcomes, Protagenic represents a compelling investment opportunity for institutional investors seeking to support innovative healthcare solutions in a crucial and evolving market.